DEPLIPIDO Study: Functional and Lipidomic Analysis of Plasma HDL in Patients With Depression Compared to Controls
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: HDRS-17 depression scale, Blood sampling.
- Who it may be relevant to
- Registry conditions: Depression. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Depression is a disabling condition in terms of psychosocial alteration and also in terms of physical comorbidities. Depression doubles the risk of myocardial infarction compared with the general population, and this cardiovascular comorbidity leads to an increase in mortality in patients suffering from depression, even exceeding suicide-related mortality. It is therefore important to better understand the mechanisms linking depression and cardiovascular disease. Among the hypotheses that may account for the increased cardiovascular risk in patients with depression, lipid abnormalities are likely to play a crucial role. Thus, qualitative and functional abnormalities in HDL lipoproteins are an important line of research, insofar as these lipid abnormalities have been recognized as important atherogenic abnormalities in populations at high cardiovascular risk, which is the case of patients with depression. In this clinical, epidemiological and scientific context, a collaborative study undertaken by both the Department of Psychiatry of the Dijon Bourgogne University Hospital of and the INSERM LNC-UMR 1231 (PADYS) Laboratory of the UNIVERSITY OF BOURGOGNE FRANCHE-COMTE is an original translational research project, and the first study to perform a lipidomic analysis of HDL, coupled with a functional analysis of these lipoproteins in depression.
Interventions
- Other HDRS-17 depression scale
Measuring the severity of depression - Biological Blood sampling
3 tubes of 5 ml
Primary outcome measures
- Measurement of cholesterol efflux by fluorescent method on THP-1 cell derived macrophages [Time frame: At baseline]
Eligibility criteria
Inclusion criteria
- FOR PATIENTS WITH RECURRENT DEPRESSION :
- Patient who has provided oral consent
- Adult with moderate to severe depression according to DSM-5 criteria (Hamilton HDRS-17 score ≥ 18), with a number of depressive episodes ≥ 3
- PATIENTS PRESENTING WITH A FIRST DEPRESSIVE EPISODE
- Patient who has provided oral consent
- Adult with moderate to severe characterized depression according to DSM-5 criteria (Hamilton HDRS-17 scale score ≥ 18) presenting with a first depressive episode.
- CONTROLS
- Person who has provided oral consent
- Adult who has never shown signs of depression
Exclusion criteria
- Person not affiliated with national health insurance
- Person subject to a measure of legal protection (curatorship, guardianship)
- Pregnant or breastfeeding women
- Adult unable to express consent
- Minors
- Person with a metabolic syndrome (according to NCEP/ATP-III criteria: 3 of the following 5 criteria: Waist circumference ≥ 102 cm in males and ≥ 88cm in females, Triglycerides > 1.50 g/L, HDL-Cholesterol < 0.40 g/L in H, HDL-Cholesterol < 0.50 g/L in F, Blood pressure ≥130/85mmHg, Fasting blood glucose ≥ 1.10 g/L),
- Person with type 1 or type 2 diabetes,
- Person with a mild depressive episode (HDRS-17<18),
- Person with concomitant antipsychotic treatment
- Person with bipolar disorder,
- Person with a moderate to severe alcohol use disorder according to DSM-5 criteria
- Person with schizophrenia,
- Person with a persistent delusional disorder,
- Person with an autism spectrum disorder.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Other
Study locations
France · 1 center
- Chu Dijon Bourgogne — Dijon
Identifiers
NCT: NCT05099341 · CHAUVET CRBFC-E 2019